Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomised, double-blind, placebo-controlled study

被引：120

作者：

De Grandis D. ^{[1
]}

Minardi C. ^{[2
]}

机构：

[1] Department of Neuroscience, Ospedale Civile, I-45100 Rovigo

[2] Neurology Unit, Bufalini Hospital, Cesena

来源：

Drugs in R & D | 2002年 / 3卷 / 4期

关键词：

Nerve Growth Factor; Diabetic Neuropathy; Nerve Conduction Velocity; Aldose Reductase Inhibitor; Electrophysiological Parameter;

D O I：

10.2165/00126839-200203040-00001

中图分类号：

学科分类号：

摘要：

Objective: To assess the efficacy and tolerability of acetyl-L-carnitine (levacecarnine; LAC) versus placebo in the treatment of diabetic neuropathy, mainly by evaluating the effects of treatment on electrophysiological parameters and pain symptoms. Design: This was a multicentre (n = 20), randomised, double-blind, placebo-controlled, parallel-group study. Patients: 333 patients meeting clinical and/or neurophysiological criteria for diabetic neuropathy were enrolled. Interventions: Patients were randomised to treatment with LAC or placebo. LAC (or placebo) was started intramuscularly at a dosage of 1000 mg/day for 10 days and continued orally at a dosage of 2000 mg/day for the remainder of the study (355 days). Main outcome parameters and results: The main efficacy parameter was the effect of treatment on 6- and 12-month changes from baseline in nerve conduction velocity (NCV) and amplitude in the sensory (ulnar, sural and median) and motor (median, ulnar and peroneal) nerves. The effect of treatment on pain was also evaluated by means of a visual analogue scale (VAS). Among the 294 patients with impaired electrophysiological parameters at baseline, those treated with LAC showed a statistically significant improvement in mean NCV and amplitude compared with placebo (p < 0.01). The greatest changes in NCV (at 12 months) were observed in the sensory sural nerve (+5.7 m/sec in the LAC group vs + 1.0 m/sec in the placebo group), sensory ulnar nerve (+2.9 vs +0.1 m/sec, respectively) and motor peroneal nerve (+2.7 vs -0.2 m/sec), whereas the greatest changes in amplitude were recorded in the motor peroneal nerve (+2.2 vs +0. 1mV). After 12 months of treatment, mean VAS scores for pain were significantly reduced from baseline by 39% in LAC-treated patients (p < 0.0 vs baseline) compared with 8% in placebo recipients. LAC was well tolerated over the study period. Conclusions: LAC was effective and well tolerated in improving neurophysiological parameters and in reducing pain over a 1-year period. LAC is, therefore, a promising treatment option in patients with diabetic neuropathy.

引用

页码：223 / 231

页数：8

共 42 条

[21]

Ido Y., McHowatt J., Chang K.C., Et al., Neuronal dysfunction and metabolic imbalances in diabetic rats: Prevention by acetyl-L-carnitine, Diabetes, 43, pp. 1469-1477, (1994)

[22]

De Grandis D., Santoro L., Di Benedetto P., L-Acetylcarnitine in the treatment of patients with peripheral neuropathies: A short-term, double-blind, clinical study of 426 patients, Clin. Drug Invest., 10, pp. 317-322, (1995)

[23]

De Grandis D., Tolerability and efficacy of L-acetylcarnitine in patients with peripheral neuropathies: A short-term, open multicentre study, Clin. Drug Invest., 15, pp. 73-79, (1998)

[24]

Quatraro A., Roca P., Donzella P., Et al., Acetyl-L-carnitine for symptomatic diabetic neuropathy, Diabetologia, 38, (1995)

[25]

Feldman E.L., Stevens M.J., Thomas P.K., Et al., A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy, Diabetes Care, 17, pp. 1281-1289, (1994)

[26]

Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy, Neurology, 42, pp. 1823-1839, (1992)

[27]

Kimura J., Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice, (2001)

[28]

Scott J., Huskisson E.C., Graphic representation of pain, Pain, 2, pp. 175-184, (1976)

[29]

The effect of intensive diabetes therapy on the development and progression of neuropathy, Ann. Intern. Med., 122, pp. 561-568, (1995)

[30]

Gaster B., Hirsch I., The effects of improved glycemic control on complications in type 2 diabetes, Arch. Intern. Med., 158, pp. 134-140, (1998)

← 1 2 3 4 5 →